Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase – Interim Reporting

With disclosure dated September 22, 2021, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the beginning of a second tranche of up to USD 19.4 million starting on September 27, 2021 under the share repurchase program originally announced on July 12, 2021.

The number of shares which have been bought back within the framework of such tranche of the share repurchase program in the time period from September 27, 2021 until and including October 1, 2021, amounts to 74,737 shares.

Shares were bought back as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Number of Shares acquired</th>
<th>Average Price (EUR)</th>
<th>Purchased Volume (EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>27- September -2021</td>
<td>20,000</td>
<td>45.5068</td>
<td>910,136.00</td>
</tr>
<tr>
<td>28- September -2021</td>
<td>10,000</td>
<td>44.1507</td>
<td>441,507.00</td>
</tr>
<tr>
<td>29- September -2021</td>
<td>14,881</td>
<td>44.4775</td>
<td>661,869.68</td>
</tr>
<tr>
<td>30- September -2021</td>
<td>15,000</td>
<td>44.7835</td>
<td>671,752.50</td>
</tr>
<tr>
<td>01- October -2021</td>
<td>14,856</td>
<td>43.9280</td>
<td>652,594.37</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>74,737</strong></td>
<td><strong>44.6614</strong></td>
<td><strong>3,337,859.55</strong></td>
</tr>
</tbody>
</table>

The underlying individual trades are published on the website of QIAGEN N.V. (https://corporate.qiagen.com/investor-relations/stock-information/share-buyback/default.aspx).

The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.

Venlo, 5 October 2021

Managing Board

Contacts:

**QIAGEN**

**Investor Relations**
John Gilardi  
e-mail: ir@qiagen.com

**Public Relations**
Dr. Thomas Theuringer  
e-mail: pr@qiagen.com

+49 2103 29 11711  
+49 2103 29 11826  

Sample to Insight